Literature DB >> 25806194

Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer.

Antonio Passaro1, Enrico Cortesi1.   

Abstract

Entities:  

Year:  2012        PMID： 25806194      PMCID： PMC4367551          DOI： 10.3978/j.issn.2218-6751.2012.09.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  Revisions in the International System for Staging Lung Cancer.

Authors:  C F Mountain
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

Review 2.  Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.

Authors:  Fausto Petrelli; Karen Borgonovo; Mary Cabiddu; Sandro Barni
Journal:  Clin Lung Cancer       Date:  2011-11-06       Impact factor: 4.785

Review 3.  Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Authors:  C Gridelli; F De Marinis; M Di Maio; D Cortinovis; F Cappuzzo; T Mok
Journal:  Lung Cancer       Date:  2011-01-08       Impact factor: 5.705

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Authors:  J A Roth; F Fossella; R Komaki; M B Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; M McGavran
Journal:  J Natl Cancer Inst       Date:  1994-05-04       Impact factor: 13.506

6.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal:  N Engl J Med       Date:  1994-01-20       Impact factor: 91.245

7.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer.

Authors:  Toshihiro Osaki; Tsunehiro Oyama; Chun-Dong Gu; Toshihiro Yamashita; Tomoko So; Mitsuhiro Takenoyama; Kenji Sugio; Kosei Yasumoto
Journal:  J Clin Oncol       Date:  2002-07-01       Impact factor: 44.544

9.  Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance.

Authors:  Ottavio Rena; Luca Carsana; Silvia Cristina; Esther Papalia; Fabio Massera; Luca Errico; Cristina Bozzola; Caterina Casadio
Journal:  Eur J Cardiothorac Surg       Date:  2007-11-01       Impact factor: 4.191

Review 10.  Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.

Authors:  Maria Bonomi; Sara Pilotto; Michele Milella; Francesco Massari; Sara Cingarlini; Matteo Brunelli; Marco Chilosi; Giampaolo Tortora; Emilio Bria
Journal:  J Exp Clin Cancer Res       Date:  2011-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.